The Impact Of Platelet Function on 1-year Outcome in Complex PCI Patients
1 other identifier
observational
1,440
1 country
1
Brief Summary
To identify the optimal cut-off values in different platelet function testing to predict MACCE at 12-months in complex PCI patients of China
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 20, 2017
CompletedFirst Posted
Study publicly available on registry
November 27, 2017
CompletedStudy Start
First participant enrolled
November 29, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 29, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 29, 2021
CompletedJanuary 25, 2018
January 1, 2018
3.7 years
November 20, 2017
January 24, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Optimal cut-off values in different platelet function testing to predict MACCE at 12-months in complex PCI patients of China
Within 12 months of patient enrolled
Secondary Outcomes (1)
Effectiveness and sensitivity of predicting between different platelet function testing
Within 12 months of patient enrolled
Eligibility Criteria
Patients with complex PCI were defined as having at least 1of the following features :3 vessels treated,≥3 stents implanted, ≥3 lesions treated,bifurcation with 2stents implanted ,total stent length \>60 mm or chronic total occlusion.
You may qualify if:
- Documented undergoing complex PCI in 1 year prior to enrollment.
You may not qualify if:
- Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language where interpreter services are not reliably available, psychiatric disturbances, alcohol or drug abuse).
- Presence of serious/severe co-morbidities in the opinion of the investigator which may limit life expectancy (\<1 year).
- Current participation in a blinded randomized clinical trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chinese Academy of Medical Sciences Fuwai Hospital
Beijing, Beijing Municipality, 100037, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yida Tang, MD, PhD
Chinese Academy of Medical Sciences, Fuwai Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, Chief Physician
Study Record Dates
First Submitted
November 20, 2017
First Posted
November 27, 2017
Study Start
November 29, 2017
Primary Completion
July 29, 2021
Study Completion
July 29, 2021
Last Updated
January 25, 2018
Record last verified: 2018-01